Search

Displaying results 7081 - 7090 of 10000 in total
  1. Drug

    Edonerpic

    go.drugbank.com/drugs/DB05938
    Investigational

    Edonerpic is a neurotrophic agent intended for the treatment of Alzheimer's disease which is under phase I clinical trial.

  2. Drug

    Peginterferon alfacon-1

    go.drugbank.com/drugs/DB05860
    Experimental

    PEGylation is a technology for the chemical attachment of polyethylene glycol (PEG) polymer chains to a broad range of drug substances such as peptides and proteins including antibody fragments; small molecules, and other drugs. [Inferge...

  3. Drug

    Hydrocortisone cypionate

    go.drugbank.com/drugs/DB14541
    ApprovedVet approvedWithdrawn

  4. Drug

    Hydrocortisone acetate

    go.drugbank.com/drugs/DB14539
    ApprovedInvestigationalVet approved

    Mixtures: Analpram E, Analpram E
  5. Drug

    Hydrocortisone valerate

    go.drugbank.com/drugs/DB14544
    ApprovedVet approved

  6. Drug

    Pentaglobin

    go.drugbank.com/drugs/DB15865
    Investigational

    Pentaglobin, also known as IgM-enriched immunoglobulin, falls under a group of polyclonal immunoglobulin preparations. It is comprised of immunoglobulin G (IgG) (https://www.drugbank.ca/drugs/DB00028) and immunoglobulin A (IgA) while als...

  7. Drug

    Dengue tetravalent vaccine, live

    go.drugbank.com/drugs/DB14764
    ApprovedInvestigational

  8. Drug

    Taribavirin

    go.drugbank.com/drugs/DB06408
    Investigational

  9. Drug

    Paquinimod

    go.drugbank.com/drugs/DB13118
    Investigational

    The disease affects mainly women of fertile age and progresses in flares with relatively symptom free periods in between. … Paquinimod is developed for the treatment of SLE (Systemic Lupus Erythematosus), which is an autoimmune disease.

  10. Drug

    Tyramine

    go.drugbank.com/drugs/DB08841
    InvestigationalNutraceutical

    There have been reports of hypertensive crisis in patients ingesting tyramine-rich diet in conjunction with monoamine oxidase inhibitors (MAOIs). … An important characteristic of this product is its impediment to cross the blood-brain barrier which restrains its side effects to only nonpsychoactive peripheral sympathomimetic effects.